ELTXElicio Therapeutics, Inc.
Is Elicio Therapeutics struggling financially?
Yes, by its own account. Elicio Therapeutics told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $79.9M
- Source filing
- 10-Q 11 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
6months
If the burn speeds up
Empty by Dec 2026
-
9months
If it eases off
Empty by Mar 2027
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$23.5M
÷
Cash burned over the last 12 months
$37.0M
What Elicio Therapeutics told the SEC
…the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this…
Elicio Therapeutics, Inc., Form 10-Q, filed 11 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 29.1% share-count increase The company issued stock. Each share now owns 22.5% less of the business than a year ago, before any change in the price.
- Cash burn is narrowing It is spending 44% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- AZTR Azitra $8.0M
- MRKR Marker Therapeutics $23.2M
- INTS Intensity Therapeutics $15.9M
- VRCA Verrica Pharmaceuticals $82.8M
- REVB Revelation Biosciences $4.3M
- BFRG Bullfrog AI Holdings $10.8M